Acute encephalopathy as a presenting sign of
suspected lupus cerebritis
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INTRODUCTION
Systemic lupus erythematous (SLE) is a chronic autoimmune condition that
can affect any organ system, and may involve the nervous system; and can
present with a number of different neurologic and psychiatric
syndromes Heller. Central nervous system neuropsychiatric lupus refers to the
various psychiatric and neurologic manifestations that develop secondary to
involvement of the CNS in patients with SLE Heller. The term lupus cerebritis
refers to the neuropsychiatric manifestations of lupus that appear to have an
organic, rather than psychiatric basis, rather than a pathophysiologic
mechanism Heller. For most phenotypic manifestations of neuropsychiatric SLE,
no biomarkers or diagnostic tests are specific enough to attribute neurologic
diagnosis to SLE, thus diagnosis of neuropsychiatric SLE nearly always
requires rigorous exclusion of other causes Gelfand.

IMAGING

The patient underwent comprehensive multiorgan imaging evaluation given her constellation of
symptoms. This included magnetic resonance imaging of the neuraxis. Brain MRI did not reveal
evidence of ischemia, and contrast sequences were not revealing of underlying infection or mass
lesion. Spinal MR imaging was unrevealing for mass lesions or inflammatory processes. She
underwent serial electroncephalography (EEG) monitoring given that her initial presentation involved
a witnessed seizure. Multiple EEGs were performed, demonstrating bihemispheric slowing without
evidence of epileptiform discharges. These EEG findings are consistent with non-specific
encephalopathy, which corresponded with the patient’s initial clinical exam. As the patient’s
mentation slowly improved and she became alert and oriented, serial EEG monitoring was no
longer indicated and thus further studies were not performed.
CT angiogram of the head was performed to evaluate for vasculitis given the concern for autoimmune
disease. This study revealed patent vasculature throughout both cerebral hemispheres and in the
posterior circulation. There was no evidence of vascular malformation,
including aneurysms, fistulas, dissections or stenosis. Part of the patient’s routine evaluation entailed
a trans thoracic echocardiogram (TTE), which incidentally revealed a large pericardial effusion. She
underwent repeat TTE following intervention and treatment which confirmed resolution of
the effusion.

HOSPITAL COURSE
The case we present is of a 38 year old African American female, who had no
significant medical history other than a remote history of head trauma with
two associated seizures that had occurred over fifteen years prior to her
hospitalization. The patient presented to the hospital with acute
encephalopathy and possible seizure like activity that occurred prior to
arrival.
The patient had a complicated hospital course. Upon initial presentation
patient was noted to be febrile and tachycardic, a lumbar puncture was
performed and CSF studies noted a lymphocytic predominant pleocytosis and
a negative meningoencephalitis panel. Patient was loaded and started on
Keppra given the concern for seizure like activity prior to hospital arrival, had
multiple EEGs that were negative for any epileptiform activity and had imaging
of her Neuro-axis which was essentially unremarkable. She also underwent a
CTA head/neck which was unremarkable and was unfortunately unable
to tolerate a four vessel angiogram to assess for findings consistent with
vasculitis. The patient was also found to have a pleural effusion and
underwent thoracentesis, in which fluid studies were consistent with an
exudative effusion, patient also underwent extensive laboratory testing which
was essentially unremarkable other than the fact that serological testing
for lupus came back positive, rheumatology was consulted, and the decision
to start the patient on steroids in addition to mycophenolate mofetil was
made for the diagnosis of SLE, only after the course of steroids and being on
an immunosuppressant agent, did the patient begin to respond and follow
commands allowing for a successful extubation.

DISCUSSION

Lupus cerebritis is an aggressive diagnostic entity that requires prompt and thorough
evaluation, as it responds well to treatment. Diagnostic dilemmas are myriad in such cases, as
the abundance of symptoms as well as multiorgan system involvement clouds the differential
diagnosis. Neuropsychiatric symptoms of lupus cerebritis are not always present in patients
who are newly diagnosed with SLE. Estimates are that between 28% and 40% of patients with a
new diagnosis of SLE manifest neuropsychiatric symptoms.
The numerous neuropsyhiatric symptoms in SLE are often characterized on central nervous
system (CNS) and peripheral nervous system (PNS) involvement. CNS symptoms include aseptic
meningitis, cerebrovascular disease, cognitive dysfunction, headache, demyelinating
syndromes, movement disorders, seizure disorders and transverse myelopathy. PNS symptoms
include autonomic neuropathy, peripheral neuropathy, and sensorineural hearing loss.
Mechanisms by which SLE provoke neuropsychiatric symptoms include autoantibody
production, microangiopathy, production of proinflammatory cytokines, and atherosclerosis.
The most common microscopic brain findings in the CNS are microvasculopathy. This case
demonstrates some of the many neurological findings associated with lupus
cerebritis provoked by untreated SLE. The inflammatory state triggers headache, and irritation
of brain parenchyma ultimately provokes seizures. Cortical irritation breaks down the blood
brain barrier and precipitates cognitive dysfunction, as cytokines infiltrate brain tissue.
Once the diagnosis is confirmed, treatment is effective and well tolerated. Symptomatic
treatment is always warranted. As in our patient, antiseizure medications are often part of the
treatment regimen. Steroids are the mainstay of SLE treatment, and coincidentally can also
help with headache. As treatment progresses, encephalopathy and cognitive dysfunction
improve with diminution of the inflammatory state. Most patients with SLE will eventually
require chronic autoimmmune therapy, as our patient was placed on, and may be able to taper
off symptomatic neurologic treatments, provided that they do not suffer permanent central
nervous system damage.
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Fig 1 – Post-contrast MRI imaging did not reveal meningeal irritation to suggest underlying infection.
Fig 2 – Fluid attenuation inversion recovery sequence of MRI images demonstrates that brain
parenchyma is preserved, with no evidence of microvascular ischemia.

Patients presenting with acute central nervous system manifestations of SLE generally require
treatment in an intensive care unit with neuroimaging capabilities. Treatment modalities
generally vary in regards to the degree of severity of the acute attack, and a consulting
Rheumatologist should be in cooperation. There is varied evidence on a logical therapeutic
approach to the treatment of cerebral lupus due to the various pathogenesis. However, in
general treatments consist of high dose IV corticosteroid regiments, antimalarials, cytotoxic
agents such as cyclophosphamide, azathioprine, methotrexate or
investigational pharmacological approaches such as Mycophenolate mofetil; which was used in
our patient. Prognosis regarding CNS specific statistics are not available, however neurological
complications generally worsen prognosis, in the setting of refractory seizures, encephalopathy,
or paralysis from myelopathy or stroke. The overall outcome and quality of life for patients with
CNS lupus manifestations can be enhanced with close follow up and coordination between
the patient’s Neurologist, Rheumatologist, and Primary Care Physician.

ACKNOWLEDGEMENTS

This presentation was completed under the Valley Hospital Medical Center GME Program. We would like to
thank our faculty in the department of Neurology, Internal Medicine, and Pulmonology/Critical Care for their
continued support and guidance throughout the case. Thank you to Dr. Scott Harris at Touro University
Nevada, for his contributions and assistance.

REFERENCES
Eval Muscal, Robin L. Brey. Neurological Manifestations of Systemic Lupus Erythematosus in Children and Adults. Neurologic Clinics. Volume 28 Issue 1. February 2010. Pages 61-73
Gelfand, J. M., MD, MAS, FAAN, & Yazdany, J., MD, MPH. (n.d.). Uptodate. Retrieved March 26, 2021, from https://www.uptodate.com/contents/neurologic-and-neuropsychiatric-manifestations-of-systemic-lupuserythematosus?source=history_widget
Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985; 12:916.

